Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024
28 oct. 2024 07h00 HE
|
Purespring Therapeutics
Results from the study underpin the potential of Purespring’s lead AAV gene therapy programme, PS-002, as an important novel modality to treat IgAN Data support progression towards a Phase I/II...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
09 oct. 2024 07h00 HE
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
09 oct. 2024 02h00 HE
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Purespring Therapeutics presents preclinical data at the 61st ERA Congress
24 mai 2024 10h57 HE
|
Purespring Therapeutics
Purespring Therapeutics presents preclinical data at the 61st ERA Congress Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to replace defective genes or to...
Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer
06 sept. 2023 07h00 HE
|
Purespring Therapeutics
Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer Appointments of Fredrik and Peter complete build-out of senior team London— 6 September...
Purespring Therapeutics appoints Sachin Kelkar as Chief Financial Officer following appointment of Julian Hanak as Chief Executive Officer
02 août 2023 07h00 HE
|
Purespring Therapeutics
Senior leadership team strengthened as Purespring prepares kidney gene therapy programmes for clinical development London— 2 August 2023— Purespring Therapeutics, the pioneering gene therapy...
Purespring Therapeutics strengthens scientific leadership with the appointment of Alice Brown as Chief Scientific Officer
07 sept. 2022 07h00 HE
|
Purespring Therapeutics
Purespring Therapeutics strengthens scientific leadership with the appointment of Alice Brown as Chief Scientific Officer London— 07 September 2022— Purespring Therapeutics, a pioneering gene therapy...
Purespring Therapeutics strengthens scientific leadership with the appointment of Alice Brown as Chief Scientific Officer
07 sept. 2022 02h00 HE
|
Purespring Therapeutics
Purespring Therapeutics strengthens scientific leadership with the appointment of Alice Brown as Chief Scientific Officer London— 07 September 2022— Purespring Therapeutics, a pioneering gene therapy...
Purespring Therapeutics Expands Senior Team with Key Appointments
26 juil. 2022 02h00 HE
|
Purespring Therapeutics
Purespring Therapeutics Expands Senior Team with Key Appointments Appointments include Dr Pille Harrison as VP of Clinical Development, Dr Aoife Waters as Medical Director, Nick Cetateanu as Head of...
Purespring Therapeutics and SwanBio Therapeutics announce licensing agreement for use of FunSel screening platform
18 juil. 2022 07h00 HE
|
Purespring Therapeutics
Purespring Therapeutics and SwanBio Therapeutics announce licensing agreement for use of FunSel screening platform FunSel is Purespring’s proprietary in-vivo ‘gene search engine’, which allows...